These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 37492237)

  • 1. Responding to COVID-19 vaccine-related safety events: WHO Western Pacific regional experience and lessons learned.
    Cho H; Amarasinghe A; Takashima Y
    Western Pac Surveill Response J; 2023; 14(2):1-6. PubMed ID: 37492237
    [TBL] [Abstract][Full Text] [Related]  

  • 2. COVID-19 vaccine-related adverse events following immunization in the WHO Western Pacific Region, 2021-2022.
    Amarasinghe A; Cho H; Katalbas ER; Takashima Y
    Western Pac Surveill Response J; 2023; 14(2):1-11. PubMed ID: 37492235
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adverse events of special interest and mortality following vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines in Hong Kong: A retrospective study.
    Wong CKH; Lau KTK; Xiong X; Au ICH; Lai FTT; Wan EYF; Chui CSL; Li X; Chan EWY; Gao L; Cheng FWT; Tang SCW; Wong ICK
    PLoS Med; 2022 Jun; 19(6):e1004018. PubMed ID: 35727759
    [TBL] [Abstract][Full Text] [Related]  

  • 4. COVID-19 vaccines and thrombosis with thrombocytopenia syndrome.
    Lai CC; Ko WC; Chen CJ; Chen PY; Huang YC; Lee PI; Hsueh PR
    Expert Rev Vaccines; 2021 Aug; 20(8):1027-1035. PubMed ID: 34176415
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-Term Safety Analysis of the ChAdOx1-nCoV-19 Corona Virus Vaccine: Results from a Prospective Observational Study in Priority Vaccinated Groups in North India.
    Kaur U; Fatima Z; Maheshwari K; Sahni V; Dehade A; Kl A; Yadav AK; Kansal S; Jaisawal V; Chakrabarti SS
    Drug Saf; 2023 Jun; 46(6):553-563. PubMed ID: 37133805
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advancing the Science of Vaccine Safety During the Coronavirus Disease 2019 (COVID-19) Pandemic and Beyond: Launching an International Network of Special Immunization Services.
    Top KA; Chen RT; Levy O; Ozonoff A; Carleton B; Crawford NW; Creech CB; Kochhar S; Poland GA; Gutu K; Cutland CL
    Clin Infect Dis; 2022 Aug; 75(Suppl 1):S11-S17. PubMed ID: 35680552
    [TBL] [Abstract][Full Text] [Related]  

  • 7. COVID-19 vaccine policy development in a sample of 44 countries - Key findings from a December 2021 survey of National Immunization Technical Advisory Groups (NITAGs).
    Kahn AL; Steffen CA; Henaff L; MacDonald NE; Morgan C; Faden R; Olayinka F; Desai S
    Vaccine; 2023 Jan; 41(3):676-683. PubMed ID: 36494252
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
    Akova M; Unal S
    Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence and management of the main serious adverse events reported after COVID-19 vaccination.
    Padilla-Flores T; Sampieri A; Vaca L
    Pharmacol Res Perspect; 2024 Jun; 12(3):e1224. PubMed ID: 38864106
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety of the Fiocruz ChAdOx COVID-19 vaccine used in a mass vaccination campaign in Botucatu, Brazil.
    Clemens SAC; Fortaleza CMCB; Crowe M; Pollard A; Tasca KI; Grotto RMT; Martins MR; Spadaro AG; Barretti P; Verstraeten T; Clemens R
    Vaccine; 2022 Nov; 40(47):6722-6729. PubMed ID: 36055876
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of COVID-19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen (Johnson & Johnson) and mRNA COVID-19 Vaccines (Pfizer-BioNTech and Moderna): Update from the Advisory Committee on Immunization Practices - United States, July 2021.
    Rosenblum HG; Hadler SC; Moulia D; Shimabukuro TT; Su JR; Tepper NK; Ess KC; Woo EJ; Mba-Jonas A; Alimchandani M; Nair N; Klein NP; Hanson KE; Markowitz LE; Wharton M; McNally VV; Romero JR; Talbot HK; Lee GM; Daley MF; Mbaeyi SA; Oliver SE
    MMWR Morb Mortal Wkly Rep; 2021 Aug; 70(32):1094-1099. PubMed ID: 34383735
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Background rates of adverse events of special interest for COVID-19 vaccines: A multinational Global Vaccine Data Network (GVDN) analysis.
    Phillips A; Jiang Y; Walsh D; Andrews N; Artama M; Clothier H; Cullen L; Deng L; Escolano S; Gentile A; Gidding G; Giglio N; Junker T; Huang W; Janjua N; Kwong J; Li J; Nasreen S; Naus M; Naveed Z; Pillsbury A; Stowe J; Vo T; Buttery J; Petousis-Harris H; Black S; Hviid A
    Vaccine; 2023 Oct; 41(42):6227-6238. PubMed ID: 37673715
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterising the background incidence rates of adverse events of special interest for covid-19 vaccines in eight countries: multinational network cohort study.
    Li X; Ostropolets A; Makadia R; Shoaibi A; Rao G; Sena AG; Martinez-Hernandez E; Delmestri A; Verhamme K; Rijnbeek PR; Duarte-Salles T; Suchard MA; Ryan PB; Hripcsak G; Prieto-Alhambra D
    BMJ; 2021 Jun; 373():n1435. PubMed ID: 35727911
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Global Outbreak Alert and Response Network deployments during the COVID-19 pandemic, WHO Western Pacific Region.
    Salmon S; Brinkwirth S; Loi G; Basseal JM
    Western Pac Surveill Response J; 2024; 15(5 Spec edition):1-7. PubMed ID: 38510816
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vaccine safety in Australia during the COVID-19 pandemic: Lessons learned on the frontline.
    Laemmle-Ruff I; Lewis G; Clothier HJ; Dimaguila GL; Wolthuizen M; Buttery J; Crawford NW
    Front Public Health; 2022; 10():1053637. PubMed ID: 36408022
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Background incidence rates of adverse events of special interest related to COVID-19 vaccines in Ontario, Canada, 2015 to 2020, to inform COVID-19 vaccine safety surveillance.
    Nasreen S; Calzavara A; Buchan SA; Thampi N; Johnson C; Wilson SE; Kwong JC;
    Vaccine; 2022 May; 40(24):3305-3312. PubMed ID: 35527057
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anaphylaxis and Related Events Following COVID-19 Vaccination: A Systematic Review.
    Paul P; Janjua E; AlSubaie M; Ramadorai V; Mushannen B; Vattoth AL; Khan W; Bshesh K; Nauman A; Mohammed I; Bouhali I; Khalid M; Zakaria D
    J Clin Pharmacol; 2022 Nov; 62(11):1335-1349. PubMed ID: 35794852
    [TBL] [Abstract][Full Text] [Related]  

  • 18. COVID-19 vaccines: concerns beyond protective efficacy and safety.
    Lai CC; Chen IT; Chao CM; Lee PI; Ko WC; Hsueh PR
    Expert Rev Vaccines; 2021 Aug; 20(8):1013-1025. PubMed ID: 34180347
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of Interoperable Computable Phenotype Algorithms for Adverse Events of Special Interest to Be Used for Biologics Safety Surveillance: Validation Study.
    Holdefer AA; Pizarro J; Saunders-Hastings P; Beers J; Sang A; Hettinger AZ; Blumenthal J; Martinez E; Jones LD; Deady M; Ezzeldin H; Anderson SA
    JMIR Public Health Surveill; 2024 Jul; 10():e49811. PubMed ID: 39008361
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Imprecision in adverse event reports following immunization against HPV in Japan and COVID-19 in the USA, UK, and Japan-and the effects of vaccine hesitancy and government policy.
    Inokuma Y; Kneller R
    Eur J Clin Pharmacol; 2023 Feb; 79(2):269-278. PubMed ID: 36527455
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.